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Abstract
Background: Multidrug-resistant tuberculosis (MDR-TB) drugs which is resistant to the major first-line anti-TB drugs,
Isoniazid and Rifampicin, has become a major global challenge in tuberculosis (TB) control programme. However, its
burden at community level is not well known. Thus, the aim of study was to assess the prevalence of primary and
secondary resistance to any first line anti-TB drugs and MDR TB in Hitossa District of Oromia Regional State, Central
Ethiopia.
Methods: Population based cross- sectional study was conducted on individuals aged ≥15 years. Those with
symptoms suggestive of TB were interviewed and two sputum specimens were collected from each and examined
using Lowenstein-Jensen (LJ) culture medium. Further, the isolates were confirmed by the Ziehl-Neelsen
microscopic examination method. Drug susceptibility test (DST) was also conducted on LJ medium using a
simplified indirect proportion method. The resistance strains were then determined by percentage of colonies
that grew on the critical concentration of Isoniazid, Streptomycin, Rifampicin and Ethambutol.
Results: The overall resistance of all forms of TB to any first-line anti-TB drug was 21.7 %. Of the total new and
previously treated culture positive TB cases, 15.3 and 48.8 % respectively were found to be a resistant to any of the
first-line anti-TB drugs. Further, of all forms of TB, the overall resistance of MDR-TB was 4.7 %. However, of the total
new TB cases, 2.4 % had primary while 14.3 % had secondary MDR-TB. Resistance to any of the first-line anti-TB
drugs (adjusted odd ratio (AOR), 8.1; 95 % CI: 2.26–29.30) and MDR-TB (AOR), 7.1; 95 % CI: 2.6–43.8) was found to be
linked with previous history of anti-TB treatment.
Conclusions: The study has identified a high rate of primary and secondary resistance to any of the first-line anti-
TB drugs and MDR-TB in the study area. The resistance may have resulted from sub-optimal performance of directly
observed treatment short-course (DOTS) programme in the detecting infectious TB cases and cure rates in the
study area. Anti-TB drug resistance is linked with previous TB treatment. There is a need to strengthen DOTS and
DOTS-Plus programmes and expand MDR-TB diagnostic facilities in order to timely diagnose MDR-TB cases and
provide appropriate treatment to prevent the spread of MDR-TB in Ethiopia.
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Background
Tuberculosis (TB) remains a high-priority communicable
disease that causes illness among millions of people and is
the second leading cause of death from an infectious dis-
ease worldwide [1]. The disease disproportionately affects
people in resource-poor settings, particularly those in Asia
and Africa. More than 80 % of TB cases and 78 % of
deaths from the disease occurred in developing countries
[2, 3]. In 2013, there were 9.0 million TB new cases, and
1.5 million TB deaths occurred around the globe [2].
Ethiopia has been listed as one of the 22 high-TB burden
countries with respective mortality, prevalence and inci-
dence rate of 32, 211 and 224 cases per 100,000 popula-
tion. Moreover, 11 % of patients with TB are also infected
by the Human Immunodeficiency Virus (HIV) [2].
Multidrug-resistant tuberculosis (MDR-TB) is defined
as Mycobacterium tuberculosis strain resistant to at least
the first-line anti-TB drugs of Isoniazid and Rifampicin.
[1]. MDR-TB occurs either when a person is infected
with a resistant strain or when insufficient or improper
treatment leads to drug selection of the resistant strain
[1]. When a person with no history of first-line anti-TB
treatment develops MDR-TB, it is known as primary re-
sistance to any first line anti- TB drugs and MDR-TB,
whereas when a person with a history of first-line anti-
TB treatment acquires resistance to any first line anti-
TB drugs and MDR-TB, they are respectively called sec-
ondary resistance to any first line anti-TB drugs and
MDR-TB [4].
Multidrug-resistant TB has been known to be a major
challenge in TB control programme. It has been spread-
ing rapidly across the globe, and in recent years an esti-
mated 3.5 % of new cases and 20.5 % of previously
treated TB cases have MDR-TB. In 2013, there were an
estimated 480,000 MDR-TB cases, and about 210,000
deaths were caused by MDR-TB worldwide [2]. The
prevalence of one or more drug-resistant TB and MDR-
TB varies across counties with more than half of MDR-
TB cases occurring in India, China and the Russian
Federation [2]. The most difficult and complicated form
of drug resistant TB is known as extensively drug resist-
ant tuberculosis (XDR-TB); this has been reported from
92 countries (eight from Africa including Ethiopia) [5].
Globally 9 % of MDR-TB cases have XDR-TB [2, 6].
According to the 2014 World Health Organization
(WHO) report, Ethiopia ranked 15th out of the 27 coun-
tries with the highest estimated number of multidrug
resistant tuberculosis (MDR-TB) cases. Additionally,
WHO estimated the prevalence of MDR-TB among new
TB cases in Ethiopia at 1.6 % (95 % CI, 0.9 to 2.8 %),
and among the previously treated ones at 12 % (95 % CI:
5.6 to 21 %) [2]. Furthermore, according to the 2014
National Anti-tuberculosis Drug Resistance Survey, the
prevalence of MDR-TB among new, previously treated
and overall TB cases were 2.3, 17.8 and 4.8 %, respect-
ively [7]. Moreover, study reports from Eastern, Central,
Northern and Southern Ethiopia have shown that the
prevalence of primary resistance MDR-TB ranged from
1.1 to 5.8 % [8–11] and secondary resistance MDR-TB
from 10.9 to 71.4 % [9, 10, 12, 13].
Nevertheless, to our knowledge, reports from Ethiopia
on the prevalence of MDR-TB including primary and
secondary resistance were based on reports among
health service seekers from health facilities and might
therefore be subject to selection bias [14–16].
Because of the absence of population-based studies
and adequate laboratory testing facilities in the country,
it is difficult to have a reliable estimation on the burden
of primary and secondary resistance to any first line
anti-TB drugs and MDR TB. However, this population-
based study conducted in Hitossa District of Arsi zone
Oromia Regional State, Central Ethiopia was the first at-
tempt in the country aimed at measuring the prevalence
of primary and secondary resistance to any first line
anti-TB drugs and MDR-TB.
Methods
Study setting and population
The study was conducted in Hitossa District of Arsi Zone,
Oromia Regional State in Central Ethiopia. The popula-
tion density, socio–economic state, and demographic con-
dition of Hitossa are typical representative of the entire
features of Arsi Zone. The Directly Observed Treatment,
Short-Course (DOTS) and health service coverage, the
proportion of urban–rural population and HIV preva-
lence, and the TB case notification and treatment out-
comes of Hitossa District are also similar to those of the
whole zone of Arsi. The district has an estimated popula-
tion of 178,229 people living in 23 rural and one urban
kebele (the smallest administrative unit in government
structure) [17]. Since 2010, kebeles have been further
divided into three sub-kebeles known as gote. Each gote
has about 1/3 population of the kebele [17].
Study design
Population based cross sectional study was conducted
between 1 July 2013 and 30 June 2014 to estimate the
prevalence of primary and secondary multi-drug resist-
ant to any first line anti-TB drugs and MDR-TB in
Hitossa District of Arsi Zone. For practical and eco-
nomic reasons Hitossa District was selected purposefully
and all its kebeles were included in the study. One gote
from each kebele was randomly selected, and individuals
15 years and above living in the households of the se-
lected gote were enrolled in the study. A week before the
baseline survey, pre-survey registration was carried out
in the selected gotes of the 24 kebeles. Accordingly,
61,678 individuals living in 9,454 households were
Hamusse et al. BMC Public Health  (2016) 16:593 Page 2 of 10
identified. Eligibility includes permanent residents of
15 years of age and above who could provide written
consent for willingness to participate in the study and
temporary visitors who arrived at least 15 days before
the commencement of the study. Using the above cri-
teria, 33,073 adults were identified and included in the
study.
Data collection procedures
The aims of the study and the procedures of data collec-
tion were discussed with zonal, district and kebele
leaders. A total of 24 teams with one nurse and one
health extension worker (HEW) were involved in the
data collection. Furthermore, five laboratory technicians
also took part in sputum sample collection. The whole
process of data collection was supervised by 10 health
officers. All laboratory technicians and data collectors
were selected from public health institutions in the study
district, and they were trained on TB screening tech-
niques and on how to collect and transport sputum spe-
cimen. The same team of data collectors was assigned to
each kebele for both pre-survey registration and data
collection. The survey was carried out three times at
interval of 6 months: the first at baseline, the second at
the end of the sixth month, and the third at the end of
the 12th month between 1 July 2013 and 30 June 2014.
House to house visits were carried out to identify indi-
viduals with persistent cough of more than two weeks,
fever, and loss of appetite, weight loss, blood-stained
sputum and chest pain or difficulty of breathing which
were considered as symptoms suggestive of pulmonary
TB. Individuals with such symptoms were interviewed
on their socio–economic and demographic information
and current and previous history of TB treatment. Sub-
sequently, participants with any symptom suggestive of
the illness were asked to submit two adequate recently-
discharged mucoid or muco-purulent sputum specimens
(spot-morning). The laboratory technicians collected the
sputum in sterile falcon tubes and immediately placed
them in a cold box at 4 °C, and transported them on
the same day to Adama Regional Research Center
Laboratory.
Culture and identification
On the following day of the sputum receipt, the morning
specimen was digested and decontaminated by the
standard Acetyl L-cysteine (NALC)-NaOH method [18],
followed by centrifuged at 800 X g for 15 min to concen-
trate the organisms. The sediment (pellet) was reconsti-
tuted with 2.5 ml of sterile phosphate buffer (pH 6.8) to
prepare the suspensions for the cultures. The sediments
were inoculated in to egg-based Löwenstein-Jensen (LJ)
medium slant tubes prepared based on the International
Union against Tuberculosis and Gung Disease (IUATLD)
for the primary isolation of the organisms [19]. Following
that the LJ slant tubes were incubated at 37 °C and
inspected for a period of eight weeks for the growth of
Mycobacterium tuberculosis complex. The cultures were
considered to be negative if no colonies were identified
after 8 weeks of incubation. Moreover, the isolates from
the LJ were confirmed by microscopic examination for the
presence of Acid-Fast Bacillus (AFB) using Ziehl-Neelsen
method. Moreover, susceptibility test of all isolates to
spara-nitrobenzoic acid was carried out to identify Myco-
bacterium tuberculosis complex from environmental
mycobacteria. However, all isolates were found to be
Mycobacterium tuberculosis complex [19].
Drug susceptibility test
Drug susceptibility tests(DST) were carried out using
the simplified indirect proportion method on LJ medium
[19]. The proportion method validates the percentage of
growth of distinct inoculums on a drug-free control
medium compared to growth on culture media contain-
ing the critical concentration of anti-tuberculosis drugs.
The resistant strains were determined using the percent-
age of colonies that grew on the critical concentration of
0.2 mg/l for Isoniazid, (INH), and 4 mg/l for Strepto-
mycin (STM), 40 mg/l for Rifampicin (RIF) and 2 mg/l
for Ethambutol (EMB). The isolate was said to be drug
resistant when the growth was more than or equal to
1 % of the bacterial population on the media containing
the critical concentration of each drug [19].
Data management and analysis
To ensure data quality, the principal investigator and su-
pervisors closely monitored the data collection process
in which a standardized and pre-tested questionnaire
was used. The collected data were coded and double en-
tered into Epi-info version 7 statistical software by trained
data clerks. Then they were checked against the original
information for missing variables. Errors were corrected
by referring to the original questionnaire.
The percentage of drug resistance to any of the drugs
or its combination with other drugs was determined.
The primary resistance was calculated by dividing the
number of resistant isolates among new TB cases by the
total number of new TB cases found to be culture positive
for a particular drug or combination of drugs multiplied
by 100. Similarly, percentage of secondary resistance was
calculated by dividing the number of resistant isolates in
previously treated TB cases by the total number of re-
treated TB cases found to be culture positive for that par-
ticular drug or combination of drugs multiplied by 100.
We excluded 20 contaminated cultures from the analysis
as their results were not known.
Analysis was made using IBM SPSS version 20 statis-
tical software (SPSS Inc. Chicago. 2007). Descriptive
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analysis was made and frequencies and odds ratios (OR)
with the 95 % confidence intervals (CI) were calculated.
Logistic regression analysis was used to evaluate the
association between drug resistance as outcome and
others related independent variables. A significance level
of <0.05 was considered statistically significant. We also
compare the result of current study with those of other
studies carried out in Ethiopia between 1984 and 2015
to understand the trend of drug resistance over time
(Table 4).
Results
General characteristics of the study population
A total of 61,678 individuals in 9,454 households from
the study area were identified. Of these, 33,073 were
found to be eligible, and screened for symptoms suggest-
ive of PTB. Of these, 16,888 (51 %) were males and
28,048 (84.8 %) were rural residents. The age of the re-
spondents ranged from 15 to 94 years, with a mean age
of 42.3 (±18.4 SD) years. Out of the eligible individuals,
2,758 (8.3 %) reported to have symptoms suggestive of
PTB. Among these, 1,717 (62.3 %) were females and
1041 (37.7 %) were males. Of the 2,758 suspected cases,
2, 218 (80.4 %) were new, and 540 (19.6 %) had previ-
ously been treated with first-line anti-TB drugs
(Table 1).
Drug susceptibility pattern
All the 2,758 TB suspect cases gave spot and morning
sputum for culture examination. Of these, 106 (3.8 %)
were found to be culture positive for Mycobacterium
tuberculosis. Twenty specimens were contaminated and
were therefore excluded from the analysis. From the
total 106 culture positives, 85 (80.2 %) were new,
whereas 21 (19.8 %) were previously treated patients
with first-line anti-TB drugs (Table 1). Of the 106
isolates, 83 (78.3 %) were susceptible to all first-line
anti-TB drugs (Streptomycin (STM), Isoniazid (INH),
Ethambutol (EMB) and Rifampicin (RIF)), while 23
(21.7 %) were resistant to one or to a combination of
the first-line anti-TB drugs. Five cultures (4.7 %, 95 %
CI: 2.8–6.6 %) were MDR-TB cases.
Of the 85 new M. tuberculosis isolates, primary resist-
ant strains to any first-line anti-TB drugs were observed
in 13 (15.3 %) patients. Of these, 8 (9.4 %) were resistant
to each INH and STM, 4 (4.7 %) to RIF and 3 (3.5 %) to
EMB. Primary MDR-TB was detected in 2 (2.4 %) strains
(Table 3). However, among the new cases, no isolates of
primary resistance to all first-line drugs were observed.
Primary mono-resistance to each of INH and STM was
found in two cultures (2.4 %). There was no primary
mono-resistance to RIF and EMB among the new iso-
lates (Table 2).
Moreover, out of the 21 previously treated M. tubercu-
losis isolates, strains of secondary resistance to any of
the first-line anti-TB drugs were identified in 11 (52.2 %)
patients. Of these, 6 (28.6 %), were resistant to INH, 5
(23.8 %) to STM, and 4 (19 %) to RIF. Secondary MDR-
TB was detected in 3 (14.3 %) isolates. Of these, one
(4.8 %) was found to be resistant to all first-line drugs
(Table 3). Among previously treated cases, the highest
mono-resistance was to STM with 2 (9.5 %), followed by
one (4.8 %) to each INH and EMB. However, among the
previously treated TB cases, no mono-resistance to RIF
was reported (Table 2).
Risk factors associated with drug resistance
Previous history of TB treatment, and urban residence
were independently associated with high risk of resist-
ance to any first-line anti-TB drug. Individuals with per-
vious history of TB treatment were eight times (adjusted
odd ratio (AOR), 8.1; 95 % CI: 2.3–29.3) more likely to
develop resistance to any first-line anti-TB drugs com-
pared to those with no history of previous TB treatment.
Similarly, urban residents were four times (AOR, 4.1; 95
Table 1 General characteristics of TB suspects, smear culture
positive and MDR-TB cases in Hitossa District, Arsi Zone of




TB cases (N = 106)
Sex n (%) n (%)
Male 1041 (37.7) 51 (48.1)
Female 1717 (62.3) 55 (51.9)
Total 2758 (100) 106 (100)
Age
15–24 543 (19.7) 40 (37.7)
25–34 525 (19.0) 18 (17.0)
35–44 448 (16.3) 29 (27.4)
≥ 45 1242 (45.0) 19 (17.9)
Total 2758 (100) 106 (100)
Residence
Rural 2277 (82.6) 58 (54.7)
Urban 481 (17.4) 48 (45.3)
Total 2758 (100) 106 (100)
Education
Literate 1212 (43.9) 47 (44.3)
Illiterate 1546 (56.1) 59 (55.7)
Total 2758 (100) 106 (100)
History of pervious TB treatment
No 2218 (80.4) 85 (80.2)
Yes 540 (19.6) 21 (19.8)
Total 2758 (100) 106 (100)
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% CI: 1.3–12.8) more likely to have resistance to any
first-line anti-TB drugs compared to their rural counter-
parts. Individuals who had pervious history of TB treat-
ment were nearly seven times more likely (AOR 7.1; 95
% CI: 2.6–43.8)) to have MDR-TB compared to those
who had no history of pervious exposure to anti-TB
drugs (Table 3).
Rates of anti-TB drug resistance between 1984 and 2015
A total of 18 studies that had been published between
1994 and 2015 on the primary and secondary anti-TB
drug resistance were reviewed. Results showed that
primary resistance to any drug raged from 10.7 % in
2009 to 30.1 % in 2012. Moreover, the rate of primary
MDR-TB increased from 0.6 in 1994 to 3.7 % in 2009
while that of secondary resistance to any anti-TB drugs
varied from 11.1 % in 1996/7 to 85.7 % in 2005/6. Ac-
cording to reports from the same studies, the rate of sec-
ondary MDR-TB ranged from 15.7 % in 1996/7 and
60.8 % in 2005/6 (Table 4).
Discussions
Fifteen percent of the newly diagnosed, and fifty two
percent of the previously treated TB cases were resistant
to one or more of the first-line anti-TB drugs. MDR TB
among new cases was 2.4 %, and 14.3 % among previ-
ously treated patients. Drug resistance was associated
with previous history of TB treatment and urban resi-
dence. Resistances to any one or more of first-line anti-
TB drugs and MDR-TB in the study population were
high.
In this study, the 15 % resistance to any of the first-line
anti-TB drugs among new TB cases is comparable to re-
ports from Addis Ababa and Northern Ethiopia [10, 20].
However, it is higher than reports from other African
countries [21–23] and yet lower than those from different
parts of the country and elsewhere in Africa [8, 10, 11, 13,
24–29]. Moreover, the 52 % resistance rate to one or more
first-line anti-TB drugs among previously treated TB cases
in our study is high compared to previous reports from
Ethiopia and others African counties [28–30]. However, it
Table 2 Primary and secondary drug resistance pattern to first-line anti-TB drugs among culture positive pulmonary TB cases in
Hitossa District, Arsi Zone of Oromia Region, Central Ethiopia 2015
Drug resistance pattern New cases (N = 85) Re-treated cases (N-21) Total (N = 106)
n (%) (95 % CI) n (%) (95 % CI) n (%) 95 % CI
Any R to one drug 13 (15.2 % (7.6–22.8) 11 (52.3: 30.9–73.7) 24 (22.6: 14.6–30.6)
Any INH 8 (9.4 %) 6 (28.6) 14 (13.2)
Any RIF 4 (4.7) 4 (19.0) 8 (7.5)
Any STM 8 (9.4) 5 (23.8) 13 (12.3)
Any EMB 3 (3.5) 2 (9.5) 5 (4.7)
Mono resistance 4 4 8
Only INH 2 (2.4) 1 (4.8) 3 (2.8)
Only RIF 0 0 0
Only STM 2 (2.4) 2 (9.5) 4 (3.8)
Only EMB 0 1 (4.8) 1
Two-drug resistance 7 4 11
INH + RIF 1 (1.2)* 1 (4.8) 2 (1.9)*
INH + ETM 1 (1.2) 0 1 (0.9)
INH + STM 2 (2.4) 2 (9.5) 4 (3.8)
RIF + EMB 0 0 0
RIF + STM 2 (2.4) 1 (4.8) 3 (2.8)
ETM + STM 1 (1.2) 0 1 (0.9)
Three or more-drug resistance 2 3 5
INH + RIF + EMB 0 0 0
INH + RIF + STM 1 (1.2)* 2 (9.5) 3 (2.8)*
INH + EMB + STM 1 (1.2) 0 1 (0.9)
RIF + ETM + STM 0 0 0
INH + RIF + EMB + STM 0 1 (5.9) 1 (0.9)
MDR* 2 (2.4) 3 (14.3) 5 (4.7)
NB: MDR-TB* is multi-drug resistant TB
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is lower than 54 % reported from Benin [31], 53.8 % from
Somalia [32], 58.5 % from northern Ethiopia [10], the 71.4
and 72 % from Addis Ababa City [9, 13].
The difference in resistance rate to one or more first-
line anti-TB drugs among new and previously treated
TB patients across different study settings could be
attributed to the variation in TB control programme
performance, study population, sample size and study
methods that were used across different geographical
settings. For instance, the study subjects from Addis
Ababa who had high rate of resistance stain [9, 13] were
presumptive MDR-TB cases referred for MDR-TB inves-
tigation, while those recruited for the current study in-
cluded any person 15 years age and above in the general
population who had symptoms of TB and was at low
risk of drug resistance.
Moreover, previous studies from Ethiopia and else-
where in Africa were restricted to health service seekers
at health facilities. Thus, study results from such seg-
ment of population may not indicate the real burden of
the disease at community level as compared to the
present population-based study. Likewise, the difference
in burden of the resistance cases could be due to the
time of the study; in the past the prevalence of resistant
strains which might be a potential source of infection
was not as high as they are today. For instance, in 2001,
resistance to any first-line anti-TB drug among previ-
ously treated TB patients in Arsi Zone was 31.6 % [24].
However, after 14 years, it has reached 52.3 % in the
study area. In general, the rate of primary and secondary
resistance has been increasing in Ethiopia over the
twenty years [7–12, 33–38]. Table 4 summarizes reports
of previous studies on primary and secondary resistance
compared to the current study in Ethiopia.
In the present study, previously treated TB cases were
eight times more likely to have resistance to any of the
first-line anti-TB drugs compared to new ones. The high
level of anti-TB drug resistance among previously
treated TB cases might have resulted from poor adher-
ence and follow up or inadequate drug supply. This
might result in selection of spontaneous mutation of M.
tuberculosis strains [39]. Hence, the TB control programme
has to explore reasons for such high secondary anti-TB re-
sistances in the study area.
Table 3 Pattern of drug resistance among culture-positive TB cases with different variables in Hitossa District, Arsi Zone of Oromia
Region, Central Ethiopia, 2015
Characteristics Culture positive (n = 106) MDR-TB cases (n = 5) Any TB drug resistance (n = 23)
Number COR (95 % CI) AOR (95 % CI) Number COR (95 % CI) AOR (95 % CI)
Sex
Male 51 (48.1) 2 0.71 (0.11–4.4) 0.67 (0.10–4.2) 14 1.54 (0.61–3.90) 2.5 (0.78–8.05)
Female 55 (51.9) 3 1.00 1.00 10 1.00 1:00
Total 106 (100) 5 24
Age
15–24 40 (37.7) 3 1:00 1.00 10 1.00 1:00
25–34 18 (17.0) 0 ————— ———— 6 1.5 (0.45–5.10) 2:18 (0.55–8.70)
35–44 29 (27.4) 2 0.91 (0.14–5.84) 0.90 (0.3–6.1) 6 0.63 (0.19–2.10) 0.36 (0.08–1.56)
≥ 45 19 (17.9) 0 ————— ————— 2 0.35 (0.07–1.80) 0.19 (0.03–1.35)
Total 106 (100) 5 24
Residence
Rural 58 (54.7) 1 1:00 1.00 9 1.00 1:00
Urban 48 (45.3) 4 5.18 (0.56–4.8) 4.8 (0.7–4.7) 15 2.84 (1.11–7.45) 4.1 (1.33–12.84)
Total 106 (100) 5 24
Education
Literate 47 (44.3) 3 1:00 1.00 10 1.00 1:00
Illiterate 59 (55.7) 2 0.51 (0.08–3.21) 0.63 (0.09–3.6) 14 1.31 (0.51–3.37) 1.64 (0.53–5.11)
Total 106 (100) 5 24
History of TB treatment
No 85 (80.2) 2 1:00 1.00 14 1.00 1:00
Yes 21 (19.8) 3 6.92 (1.10–44.4) 7.1 (2.6–43.8) 10 3.48 (1.29–9.44) 8:13 (2.26–29.30)
Total 106 (100) 5 24
COR Crude Odds Ratio and AOR Adjusted Odds Ratio
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Moreover, resistance to any of the first-line anti-TB
drugs was higher among urban residents when com-
pared to their rural counterparts. This is in agreement
with findings from a previous study in eastern Ethiopia
which reported resistance of 81.7 % among urban
dwellers 18.3 % among rural residents [8]. In fact, the
association between MDR-TB and urban residence is
not well established in the literature and may need fur-
ther investigation. However, the most likely reason for
the high prevalence of MDR-TB among urban residents
might be because of higher HIV prevalence in urban set-
tings and this may have increased the risk of MDR-TB
infection [27, 40]. Moreover,, the high probability of
exposure to anti-TB drugs from different sources in
urban setting and the crowded living condition may also
have contributed to increased transmission of resistant
strains.
The 2.4 % prevalence of MDR-TB among the newly
diagnosed TB cases in this study is very high compared
to the 0 % reported in 2001 from the same area [24].
Nevertheless, it is similar to the 2.3 % reported by the
2014 National Drug Resistance and also by a study con-
ducted in Addis Ababa [7, 9]. The relatively high rate of
primary MDR-TB cases in the current population-based
study could be due to the identification of the undiag-
nosed resistance cases in the community. Thus, these
findings may imply the need for intensifying active TB
case finding using community-based health extension
workers and this could help in timely identification of
undiagnosed resistant strains in Ethiopia [33].
The 14 % prevalence of MDR-TB among previously
treated TB cases obtained in this study is lower than
18 % reported by the national surveillance [7], the
20.5 % of the global estimate [1] and other reports from
elsewhere [30, 32, 41, 42]. However, it is high compared
to the 0 % prevalence report from Arsi zone in 2001 [24].
Secondary resistance is mainly a result of poor Directly
Observed Treatment Short course (DOTS) programme
and should be as taken as a serious challenge in the TB
control programme.
In this study, previously treated TB cases were more
likely to have MDR-TB than the new ones. This is
Table 4 Rate of anti-TB drug resistance in current and other studies conducted between 1984 and 2015 in Ethiopia




Rate of anti-TB resistance















Current study 2014 33073a 15.3 2.4 48.8 14.3 21.7 4.7
Demissie M et al. [34] 1994 167b 15.6 0.6
Bruchfeld et. al [22] 1996–1997 509 14.6 0.9 11.1 0 15.7 1.7
Abate et al. [35] 1998 30c 50 12
Demissie et al. [40] 1998 12.9 0.6
Gebeyehu M et al. [23] 2001 203 18.2 0 31.6 0 19.5 0
First National Drug
resistance survey [7]
2003–2005 804 1.6 11.5
Desta K et al. [36] 2004–2005 297b 27.4 0
Abate D et al. [13] 2004–2008 376c 72.9 46.3
Asmamaw et al. [25] 2004–2005 173b 21.4 0.6
Agonafir M et al. [9] 2005–2006 114c 25 2.3 85.7 63.5 60.8 38.3
Tessema B et al. [10] 2009 260 10.7 3.7 39.1 10.9 15.8 5.0
Abebe G et al. [11] 2010–2011 136b 18.4 1.5
Esmael A et al. [37] 2010–2011 230 23.6 1.8 58.5 18.5 33.5 6.5
Yimer et al. [26] 2012 112b 30.1 1.0
Seyoum et al. [8] 2011–2013 408b 23 1.1
Nigus et al. [12] 2012–2013 606b 15.3
Second National Drug
resistance survey (7)
2014 1651 2.3 17.8
Mulisa G et al. [38] 2015 439c 33.2 %
a Of the study population, 106 TB cases were diagnosed
b Only new cases
c Previously treated and now presumptive for MDR-TB
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consistent with a meta-analysis in sub-Saharan Africa
and a systematic review in Europe where a pooled risk
of MDR-TB was higher among the previously treated TB
cases as compared to the new ones [43, 44]. The overall
high level of anti-TB drug resistance among re-treated
TB cases compared to the newly diagnosed ones might
be an indication of sub-optimal DOTS and DOTS-plus
programme performance in Ethiopia.
The DOTS strategy aims to detect 70 % of infectious
TB cases and achieve 85 % cure rate in order to inter-
rupt transmission, reduce mortality and avert the emer-
gence of drug resistance [45, 46]. However, reports from
previous studies conducted in Ethiopia between 1984
and 2015 showed that the proportion of MDR-TB
among new and previously treated TB cases varies from
place to place and increased over time (Table 4). For in-
stance, over 13 years, it increased from 0 to 2.4 % among
new patients and from 0 to 14.3 % among previously
treated ones in Arsi Zone [24]. Furthermore, according
to previous reports, the fifteen years average TB case no-
tification and cure rate of the study area were as low as
51.8 and 66.9 % [47, 48] respectively, very far from the
70 % global target of TB case notification and 85 % cure
rate. Thus, the increasing trend in resistance to any TB
drug and MDR-TB over time with the low TB case notifi-
cation and cure rate in the study area may warrant alter-
native strategy to avert the emergence of drug resistance
and strengthen TB control programme in Ethiopia.
Although DOTS- plus strategy is believed to be the best
strategy to prevent emergence of MDR TB by accessing
presumptive MDR-TB cases to diagnostic and appropriate
treatment, MDR-TB patients are challenged by much
more toxic and complicated treatment of longer duration
which results in poor treatment outcome and emergence
of XDR-TB. Therefore, effective implementation of DOTS
and DOTS-plus strategies which are believed to be a cor-
ner stone in the prevention of the emergence and spread
of MDR-TB and XDR-TB should be strengthen in the
country. Thus, expanding MDR-TB diagnostic facilities
and intensifying active case findings using health exten-
sion workers is urgent issues to be addressed in order to
effectively control the increasing trend of drug resistance
TB in Ethiopia [33].
To our knowledge, this is the first population-based
study that analysed the prevalence of primary and sec-
ondary drug resistance and MDR-TB in Ethiopia. It
might also be one of the very few studies conducted in
poor resource setting. In fact, experienced and qualified
laboratory technicians carried out the smear microscopy,
sputum culture and DST to isolate M. tuberculosis and
drug resistant strain. Thus we believe that the finding
has highlighted the real burden of anti-TB drug resist-
ance at community level. However the study is not with-
out limitation. First, symptoms suggestive of TB were
used as screening mechanism. The fact that chest X-ray
was not used in the current study might have resulted in
missed asymptomatic TB cases and underestimate the
burden of the disease. Second, the current study ex-
cluded 20 contaminated sputum cultures which may
have an impact on our result.
Conclusions
The study has identified a high rate of primary and sec-
ondary resistance to any of the first-line anti-TB drugs
and MDR-TB in the study area. The high rate of anti-TB
drug resistance may have resulted from sub-optimal per-
formance of DOTS programme in detecting infectious
TB cases, and low cure rate in the study area. As anti-
TB drug resistance is linked with pervious TB treatment,
there is a need to strengthen DOTS and DOTS-Plus
programme and expand MDR-TB diagnostic facilities so
as to detect the cases in time and start appropriate treat-
ment to prevent the spread of MDR-TB in Ethiopia.
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